Literature DB >> 35443970

The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review.

Samuel J Westall1, Ram Prakash Narayanan2, Simon Watmough3, Greg Irving3, Niall Furlong2, Sid McNulty2, Sumudu Bujawansa2, Kevin Hardy2.   

Abstract

BACKGROUND: Evidence and guidelines increasingly support an individualised approach to care for people with type 2 diabetes and individualisation of glycaemic targets in response to patient factors.
METHODS: We undertook a scoping review of the literature for evidence of factors impacting upon glycated haemoglobin target individualisation in adults with type 2 diabetes. Data were analysed thematically with the themes inductively derived from article review.
FINDINGS: Evidence suggests that presence of cardiovascular disease, hypoglycaemia unawareness, severe hypoglycaemia, limited life expectancy, advanced age, long diabetes duration, frailty, cognitive impairment, disability, extensive comorbidity, diabetes distress and patient preference should inform the setting of glycaemic targets.
CONCLUSION: The management of people with diabetes is complex. In clinical practice, many patients will have a variety of factors that should be considered when personalising their care. Approaches to personalised care and glycaemic treatment targets should be undertaken as part of a shared decision-making process between physician and patient. Use of electronic records might enable greater efficiency and more widespread use of personalised care plans for people with diabetes. © Royal College of Physicians 2022. All rights reserved.

Entities:  

Keywords:  glycated haemoglobin; individualisation; patient factors; type 2 diabetes

Mesh:

Substances:

Year:  2022        PMID: 35443970      PMCID: PMC9135095          DOI: 10.7861/clinmed.2021-0764

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   5.410


  64 in total

1.  Severe hypoglycemia and risks of vascular events and death.

Authors:  Sophia Zoungas; Anushka Patel; John Chalmers; Bastiaan E de Galan; Qiang Li; Laurent Billot; Mark Woodward; Toshiharu Ninomiya; Bruce Neal; Stephen MacMahon; Diederick E Grobbee; Andre Pascal Kengne; Michel Marre; Simon Heller
Journal:  N Engl J Med       Date:  2010-10-07       Impact factor: 91.245

2.  Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.

Authors:  Victor W Zhong; Juhaeri Juhaeri; Stephen R Cole; Evangelos Kontopantelis; Christina M Shay; Penny Gordon-Larsen; Elizabeth J Mayer-Davis
Journal:  Diabetes Care       Date:  2017-07-17       Impact factor: 19.112

Review 3.  European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 diabetes mellitus. Executive summary.

Authors:  Alan J Sinclair; Giuseppe Paolisso; Marta Castro; Isabelle Bourdel-Marchasson; Roger Gadsby; Leocadio Rodriguez Mañas
Journal:  Diabetes Metab       Date:  2011-11       Impact factor: 6.041

4.  Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study.

Authors:  Craig J Currie; John R Peters; Aodán Tynan; Marc Evans; Robert J Heine; Oswaldo L Bracco; Tony Zagar; Chris D Poole
Journal:  Lancet       Date:  2010-01-26       Impact factor: 79.321

5.  The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.

Authors:  Elbert S Huang; Morgan Shook; Lei Jin; Marshall H Chin; David O Meltzer
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

6.  Variation in treatment preferences and care goals among older patients with diabetes and their physicians.

Authors:  Marshall H Chin; Melinda L Drum; Lei Jin; Morgan E Shook; Elbert S Huang; David O Meltzer
Journal:  Med Care       Date:  2008-03       Impact factor: 2.983

7.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

8.  Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.

Authors:  B E de Galan; S Zoungas; J Chalmers; C Anderson; C Dufouil; A Pillai; M Cooper; D E Grobbee; M Hackett; P Hamet; S R Heller; L Lisheng; S MacMahon; G Mancia; B Neal; C Y Pan; A Patel; N Poulter; F Travert; M Woodward
Journal:  Diabetologia       Date:  2009-08-18       Impact factor: 10.122

9.  The SWEET SPOTS study: a real-world interpretation of the 2012 American Diabetes Association Position Statement regarding individualized A1C targets.

Authors:  Nella Bieszk; Michael Grabner; Wenhui Wei; Nicole G Bonine; Judith J Stephenson
Journal:  Risk Manag Healthc Policy       Date:  2016-11-08

10.  Meeting individualized glycemic targets in primary care patients with type 2 diabetes in Spain.

Authors:  I Miñambres; J J Mediavilla; J Sarroca; A Pérez
Journal:  BMC Endocr Disord       Date:  2016-02-17       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.